| Exclusion Criteria: | 1) Macroscopic or microscopic evidence of remaining tumour. Patients should never have had any evidence of metastatic disease (including presence of tumour cells in the ascites). The isolated finding of cytokeratin positive cells in bone marrow is not considered evidence of metastatic disease for purposes of this study.
2) Carcinoembryonic antigen > 1.5 x ULN after surgery (during screening period).
3) For patients with colostomy, unwilling to delay revision until at least 28 days after treatment completion.
4) Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, not fully healed wounds, or anticipation of the need for major surgical procedure during the course of the study. Central venous access device (CVAD) for chemotherapy administration must be inserted at least 2 days prior to treatment start.
5) Previous anti-angiogenic treatment for any malignancy; cytotoxic chemotherapy, radiotherapy or immunotherapy for colon cancer.
6) Other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).
7) Females with a positive or no pregnancy test (within 7 days before treatment start) unless childbearing potential can be otherwise excluded (postmenopausal i.e. amenorrheic for at least 2 years, hysterectomy or oophorectomy).
8) Lactating women.
9) Fertile women (<2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.
10) History or evidence upon physical examination of CNS disease (e.g., primary brain tumour, seizure not controlled with standard medical therapy, any brain metastases).
11) History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for oral drug intake.
12) Clinically significant (i.e. active) cardiovascular disease. This includes, but is not limited to, the following examples: cerebrovascular accidents (</= 6 months prior to randomisation), myocardial infarction (</= 1 year prior to randomisation), uncontrolled hypertension (>140/90 mmHg) while receiving chronic medication, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, clinically significant ECG findings (e.g. QTc ≥ 440 msecs [male] 460 msecs [female] or >/= 2º AV Block, etc.).
13) Continued from Exclusion #12: Patients with pacemakers are allowed to enter the study only if they are considered as being in a stable condition. In case of doubt, the investigator should obtain a consultation with a local cardiologist. Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication.
14) Interstitial pneumonia or extensive symptomatic fibrosis of the lungs.
15) Known peripheral neuropathy >/= CTCAE v 3.0 Grade 1. Absence of deep tendon reflexes (DTRs) as the sole neurological abnormality does not render the patient ineligible.
16) Organ allografts requiring immunosuppressive therapy.
17) Serious, non-healing wound, ulcer, or bone fracture.
18) Evidence of bleeding diathesis or coagulapathy.
19) Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes.
20) Chronic, daily treatment with high-dose aspirin (>325mg/day) or clopidogrel (> 75 mg/day).
21) Chronic treatment with corticosteroids (dose of >/= 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids).
22) Serious intercurrent infections (uncontrolled or requiring treatment).
23) Known dihydropyrimidine dehydrogenase (DPD) deficiency.
24) Current or recent (within the 28 days prior to randomization) treatment with another investigational drug or participation in another investigation study.
25) Patients with known allergy to Chinese hamster ovary cell proteins or other recombinant human or humanized antibodies or any excipients of bevacizumab formulation, platinum compounds or to any other components of the study drugs.
26) History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications.
27) Presence of proteinuria at baseline as defined by: Patients with > 1g of protein/24 hr by a 24-hour urine collection.
28) Any laboratory values at baseline are as follows: Haematology - Absolute neutrophil count (ANC) < 1.5 x 10^9/L; Platelet count < 100 x 10^9/L; Haemoglobin < 9 g/dL (may be transfused to maintain or exceed this level); International Normalized Ratio (INR) > 1.5; APTT >/=1.5 x Upper Limit of Normal (ULN). Biochemistry - Total bilirubin > 1.5 x ULN; AST, ALT > 2.5 x ULN; Alkaline phosphatase > 2.5 xULN; Serum Creatinine > 1.5 x ULN or creatinine clearance </= 50 mL/min (e.g.Cockroft and Gault formula). |